SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
SCY-078 demonstrates a low potential for certain drug-drug interactions – a relevant differentiator versus the azoles, the leading antifungal class – providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing …